A combination of epigenetic drugs may be the next hope for melanoma patients who do not respond favourably to current treatments such as immunotherapy, Australian researchers say. Dual use of BET and CDK9 inhibitors has been shown to synergistically kill melanoma cells and had potent anti-tumour activity, according to in vivo and in vitro studies ...
Dual drug approach effective in ‘untreatable’ melanoma
By Michael Woodhead
31 Mar 2021